These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 20960825)

  • 1. [Pancreatic glucagon (IRG), enteroglucagon (EG)].
    Kawabe K; Ito T
    Nihon Rinsho; 2010 Jul; 68 Suppl 7():529-32. PubMed ID: 20960825
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pancreatic glucagon (IRG), enteroglucagon (EG)].
    Kawabe K; Ito T
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():493-5. PubMed ID: 16149559
    [No Abstract]   [Full Text] [Related]  

  • 3. The peculiar processing of pancreatic hormone glucagon seen in traumatized patients.
    Tanjoh K; Moriya T; Kinoshita K
    Hepatogastroenterology; 2010; 57(99-100):620-4. PubMed ID: 20698238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pancreatic glucagon and enteroglucagon in the plasma of patients with liver cirrhosis].
    Kasperska-Czyzykowa T
    Pol Arch Med Wewn; 1983; 69(4-5):315-23. PubMed ID: 6356055
    [No Abstract]   [Full Text] [Related]  

  • 5. [Proceedings: Pancreatic glucagon in the blood of diabetic patients].
    Tasaka Y; Sekine M; Yokosuka T; Iwatani M; Shizume K
    Nihon Naibunpi Gakkai Zasshi; 1974 Feb; 50(2):247. PubMed ID: 4476373
    [No Abstract]   [Full Text] [Related]  

  • 6. [Enteroglucagon (EG)].
    Sumii T; Nawata H
    Nihon Rinsho; 1999 Dec; 57 Suppl():320-2. PubMed ID: 10778128
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic pancreatitis and diabetes mellitus: plasma and gastroduodenal mucosal profiles of regulatory peptides (gastrin, motilin, secretin, cholecystokinin, gastric inhibitory polypeptide, somatostatin, VIP, substance P, pancreatic polypeptide, glucagon, enteroglucagon, neurotensin).
    Domschke S; Bloom SR; Adrian TE; Lux G; Domschke W
    Hepatogastroenterology; 1988 Oct; 35(5):229-37. PubMed ID: 2465985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pancreatic glucagon (IRG)].
    Sako Y; Umeda F
    Nihon Rinsho; 1995 Mar; 53 Su Pt 2():662-5. PubMed ID: 8753328
    [No Abstract]   [Full Text] [Related]  

  • 9. Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis.
    Knop FK; Vilsbøll T; Larsen S; Madsbad S; Holst JJ; Krarup T
    Regul Pept; 2010 Sep; 164(2-3):144-50. PubMed ID: 20573586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes.
    Hiroyoshi M; Tateishi K; Yasunami Y; Maeshiro K; Ono J; Matsuoka Y; Ikeda S
    Am J Gastroenterol; 1999 Apr; 94(4):976-81. PubMed ID: 10201468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New findings on pancreatic glucagon in diabetes].
    Hejda B
    Vnitr Lek; 1973 Aug; 19(8):816-8. PubMed ID: 4731157
    [No Abstract]   [Full Text] [Related]  

  • 12. Heterogeneity of plasma glucagon: patterns in patients with chronic renal failure and diabetes.
    Kuku SF; Zeidler A; Emmanouel DS; Katz AI; Rubenstein AH
    J Clin Endocrinol Metab; 1976 Jan; 42(1):173-6. PubMed ID: 1249185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exaggerated glucagon secretion in diabetic and non-diabetic subjects with surgical porto-caval anastomosis.
    Fallucca F; Ziparo V; Giangrande L; Menzinger G; Stipa S
    Horm Metab Res; 1981 Oct; 13(10):545-7. PubMed ID: 7298009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrepancy of fasting plasma glucagon levels measured by different glucagon antisera.
    Tahara Y; Tanaka A; Yamamoto Y; Fukuda M; Kumahara Y; Shima K
    Diabetes Res; 1988 Apr; 7(4):179-83. PubMed ID: 3402167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut glucagon-like immunoreactants.
    Moody AJ
    Clin Gastroenterol; 1980 Sep; 9(3):699-709. PubMed ID: 7000398
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. Pathophysiologic and therapeutic implications.
    Gerich JE; Lorenzi M; Schneider V; Karam JH; Rivier J; Guillemin R; Forsham PH
    N Engl J Med; 1974 Sep; 291(11):544-7. PubMed ID: 4604408
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization of response of gut GLI to fat ingestion in dogs.
    Ohneda A; Kobayashi T; Nihei J
    Horm Metab Res; 1984 Dec; 16 Suppl 1():105-9. PubMed ID: 6398248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pancreatic function tests].
    Abe M; Ikeda Y; Yaginuma M; Shimizu N
    Nihon Rinsho; 1969 Feb; 27(2):291-300. PubMed ID: 4306418
    [No Abstract]   [Full Text] [Related]  

  • 19. Changes in glucagon kinetics and processing in patients with acute pancreatitis.
    Tanjoh K; Tomita R; Ishikawa Y; Izumi T; Kinoshita K; Azuhata T
    Hepatogastroenterology; 2007 Jun; 54(76):1250-5. PubMed ID: 17629081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiency.
    Knop FK; Vilsbøll T; Lund A; Krarup T; Holst JJ; Hornum M
    JOP; 2010 Sep; 11(5):489-91. PubMed ID: 20818126
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.